指南与共识药物不良反应与药物警戒

各国风险最小化措施监管指南与RIMES清单的比较

Comparing regulatory guidance on risk minimization/mitigation and the Reporting recommendation Intended for pharmaceutical Risk Minimization Evaluation Studies checklist.
指南 / 共识 · Br J Clin Pharmacol · 2024-09-19

该研究识别了五大洲多个国家的风险最小化措施(RMM)效果评估监管指南,并与RIMES清单进行比较。结果显示,EMA和FDA指南仅部分符合RIMES,多数国家缺乏本国指南或参考EMA/FDA,全球RMM专项指南缺乏且不统一,与RIMES一致性有限。

要点

  • EMA和FDA指南与RIMES清单仅在测量和结果部分部分一致。
  • 多数国家无本国指南时推荐遵循EMA或FDA指南。
  • 全球缺乏RMM专项指南,现有指南不统一且与RIMES一致性有限。

核心结论

  • 全球范围内缺乏风险最小化措施专项监管指南,现有指南不统一且与RIMES清单一致性有限。

研究设计与样本

  • 识别五大洲多个国家(非洲:埃及、南非;亚洲:澳大利亚、中国、日本、韩国、新加坡;欧洲:欧盟27国、英国;北美:美国、加拿大;南美:巴西)的最新RMM效果评估监管指南,并与RIMES清单比较。

主要发现

  • EMA和FDA指南仅部分符合RIMES,主要在测量和结果方面。
  • 多数国家在本国无指南时推荐遵循EMA或FDA指南;日本和南非提及ICH E2E指南;巴西和中国无指南或建议。

关键数值与推荐

  • RIMES清单条目涵盖研究假设、参与者、测量、统计分析和结果。

临床怎么用

  • 临床药师在评估风险最小化措施效果时,可参考RIMES清单以提高研究质量,并注意各国指南与RIMES的有限一致性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The latest country-specific regulatory guidance for assessing effectiveness of risk minimization measures (RMM) strategies was identified across five continents-Africa (Egypt, South Africa), Asia (Australia, China, Japan, South Korea, Singapore), Europe (EU-27, United Kingdom), North America (Unites States, Canada) and South America (Brazil)-and compared to the Reporting recommendation Intended for pharmaceutical Risk Minimization Evaluation Studies (RIMES) checklist, developed to assess the quality of effectiveness evaluations and endorsed by the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). RIMES checklist items address study hypothesis, participants, measures, statistical analysis and results. European Medical Agency (EMA) and Food and Drug Administration (FDA) guidance only partially aligned with RIMES, primarily for measures and results. In the absence of country-specific guidance, most countries recommended following EMA or FDA guidelines; Japan and South Africa mentioned the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH E2E) guideline; Brazil and China had no guidance/recommendations. Worldwide, there was a lack of RMM-specific guidance and, when guidance existed, they were not harmonized, and alignment with the RIMES checklist was limited.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Guleria S, Brouwer E, Brown DA, et al. Comparing regulatory guidance on risk minimization/mitigation and the Reporting recommendation Intended for pharmaceutical Risk Minimization Evaluation Studies checklist. Br J Clin Pharmacol. 2024. PMID: 39297237. doi:10.1111/bcp.16259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。